Stem cell therapy procedure
This is a live video of stem cell therapy by intra-arterial procedure to a DMD patient. Muscualr Dystrophy Foundation India has been assisting patients in stem cell therapy in India. Please do visit http://www.mdfindia.orgFrom:MusclecampaignViews:2 0ratingsTime:01:39More inNonprofits Activism

Excerpt from:
Stem cell therapy procedure - Video

Recommendation and review posted by simmons

PURTIER PRESENTATION
Please contact Mr.SAMSIUR SAUDJANA @ JAKARTA :+6281699062 Live cell therapy is a very effective stem cell therapy for improving health and even disease treatment other than for beauty and anti-aging.From:SAMSIUR SAUDJANAViews:1 0ratingsTime:09:00More inScience Technology

View post:
PURTIER PRESENTATION - Video

Recommendation and review posted by simmons

Donna Skerrett of Mesoblast on adult stem cell therapies - at Stem Cells USA RM Congress 2012
Donna Skerrett, Chief Medical Officer of Mesoblast, presented a case study on Mesoblast and their adult stem cell therapy at the Stem Cells USA Regenerative Medicine Congress 2012. The Stem Cells Regenerative Medicine Congress is where pharma, biotech, academia, government and investors come to uncover the technologies, strategies and business models that will help get stem cell and regenerative medicine treatments to market faster and more cost effectively. For more information, go to http://www.terrapinn.com/stemcellsusa. Or, check out our blog at blogs.terrapinn.com/total-biopharma for up to date information on the stem cells, RM and cord blood banking and therapeutics sectors.From:biopharmachannelViews:0 0ratingsTime:21:30More inScience Technology

Originally posted here:
Donna Skerrett of Mesoblast on adult stem cell therapies - at Stem Cells USA

Recommendation and review posted by simmons

Animal Stem Cell Therapy
Dr Tim O #39;neill DVM hard at work showing you the amazing results of stem cell and Platlete Rich Plasma treatment.From:Greg SantiniViews:0 0ratingsTime:01:03More inPets Animals

Link:
Animal Stem Cell Therapy - Video

Recommendation and review posted by simmons

Success Rate of Stem Cell Treatments in Mexico
http://www.mexicohealth.com The video shows a pioneering stem cell surgeon discussing the success rate of stem cell treatments in Mexico. He proclaims more than 80% of his patients show a positive response to the initial therapy. Those who respond well keep returning to his clinic in Tijuana since they start seeing marked improvements in their otherwise irredeemable conditions such as, multiple sclerosis, brain damage, or heart disease. This stem cell specialist from Tijuana has cured over 40 patients for critical illnesses. Claim your FREE quote for stem cell treatments in Mexico by clicking the link above. Related Searches: Successes of Adult Stem Cell Treatments Mexico, success rate for stem cell therapy Mexico, stem cell transplant success rates Mexico, success rate of embryonic stem cells Mexico, Effectiveness of stem cell therapy mexico, stem cell transplant success mexico,From:mexicohealthViews:4 0ratingsTime:01:00More inPeople Blogs

Read the original:
Success Rate of Stem Cell Treatments in Mexico - Video

Recommendation and review posted by simmons

Treatment Plan for Stem Cells Transplantation in Mexico - Part 2
The video shows a leading stem cell therapist in Mexico discussing in detail the day wise break-up of a treatment plan for stem cell transplantation in Mexico. This is part 2 of the video. This surgeon is one of the pioneers in stem cell research and has cured over 40 patients for otherwise fatal diseases. Over 80% of the patients respond well to the initial treatment he bestows. Despite his track record, the world is still skeptical of stem cell therapies. Many who #39;ve taken a leap of faith by choosing this doctor, found it sufficiently rewarding. The doctor operates from Tijuana, Mexico and you can order a free quote for stem cell transplantation at his Mexico clinic by clicking the link above. Related Searches: stem cell therapy treatment plan mexico, Patient Treatment Plans stem cell Mexico, adult stem cell treatment mexico, autologous stem cell transplant mexico, allogeneic stem cell transplant mexico,From:mexicohealthViews:3 0ratingsTime:01:50More inPeople Blogs

View post:
Treatment Plan for Stem Cells Transplantation in Mexico - Part 2 - Video

Recommendation and review posted by simmons

Treatment Plan for Foreign Patients - Stem Cells Doctor Mexico
http://www.mexicohealth.com The video shows a top stem cell doctor from Mexico going into the details of treatment plan by breaking it up into day-wise events. The treatment lasts 4-5 days, after which the patients can return to their countries. Tijuana, the doctor #39;s home, is especially appealing to Americans as it offers geographical advantage and low cost stem cell treatments for incurable cases. True that the therapy is far from mainstream, this surgeon #39;s track record of curing over 40 patients is an insight into efficacy of the therapy. He claims more than 80% of the patients respond well to his initial therapy. Get a free quote by stem cells doctor in Mexico by clicking the link above. Related Searches: stem cell therapy treatment plan mexico, Patient Treatment Plans stem cell Mexico, adult stem cell treatment mexico, autologous stem cell transplant mexico, allogeneic stem cell transplant mexico,From:mexicohealthViews:5 0ratingsTime:03:48More inPeople Blogs

Originally posted here:
Treatment Plan for Foreign Patients - Stem Cells Doctor Mexico - Video

Recommendation and review posted by simmons

What Are Stem Cells - Mexico Specialist
http://www.mexicohealth.com The video shows a stem cell specialist from Mexico explaining in layman terms the stems cells and how they #39;re harvested. This specialist operates from Tijuana where he has been dedicated to finding a perfect recipe for different life threatening conditions and he has tasted success. With an astonishingly high initial response of over 80%, the doctor has cured over 40 patients for conditions like multiple sclerosis, brain damage, eye problems and cardiac problems. To get a free quote by Mexico specialist in stem cell therapy, click the link above. Related Searches: What are stem cells stem cell definitionFrom:mexicohealthViews:3 0ratingsTime:01:05More inPeople Blogs

Follow this link:
What Are Stem Cells - Mexico Specialist - Video

Recommendation and review posted by simmons

Stem Cell Therapy Market in Asia-Pacific to 2018 Market Research Report
Report provides (www.marketresearchreports.com an in-depth analysis on stem cell research and development in India, China, Japan, South-Korea and Singapore. The report market analysis and forecasts for CABG, LSCT, Type 1 DM, Type 2 DM, Hearticellgram, Cerecellgram, Cartistem and Cupistem. The report also provides information on trends and pipelines. In addition to this, the report covers market drivers and challenges for stem cell research market.From:MarketResearchReportViews:0 0ratingsTime:01:21More inScience Technology

Read the original post:
Stem Cell Therapy Market in Asia-Pacific to 2018 Market Research Report - Video

Recommendation and review posted by simmons

ReportsnReports.com adds Stem Cell Therapy Market in Asia-Pacific to 2018 - Commercialization Supported by Favorable Government Policies, Strong Pipeline and Increased Licensing Activity to its online market intelligence reports library.

Dallas, Texas (PRWEB) December 21, 2012

The growth in the APAC stem cell therapy market will not only provide treatment options but will also contribute significantly to the countries Gross Domestic Product (GDP), with the President of South Korea only last year referring to stem cell research as a new growth engine for the nations economy. In order to support the stem cell industry, regulatory guidelines in Asia-Pacific countries allow stem cell research, and this has led to its commercialization. India and South Korea are the leaders in the commercialization of stem cell therapy, with approved products for Acute Myocardial Infarction (AMI), osteoarthritis and anal fistula in Crohns disease, amongst others. The countries allow the use of human embryonic stem cells and provide adequate funding support for the research.

Stem cell therapy is an emerging field, and a large amount of research is currently being carried out by institutions such as hospitals, universities and medical colleges. According to this research and analysis of the stem cell therapy research in Asia-Pacific, 63% of pipeline molecules were being researched by academia. The emergence of institutional research has boosted stem cell discoveries, as companies can be put off conducting research due to uncertain therapeutic outcomes. China and Japan witness only a negligible industry presence in stem cell research, as academic institutions dominate however in contrast, India has the presence of both industry and academia. The major institutions engaged in stem cell research in India are LV Prasad Eye Institute (LYPEI) for Limbal Stem Cell Technology (LSCT), and the Post Graduate Institute of Medical Education and Research (PGIMER) for stem cell therapy for type 2 diabetes mellitus.

The market is poised for significant growth in the future, due to the anticipated launch of JCR Pharmaceuticals JR-031 in Japan in 2014, and FCB Pharmicells Cerecellgram (CCG) in South Korea in 2015. This research report (http://www.reportsnreports.com/reports/210795-stem-cell-therapy-market-in-asia-pacific-to-2018-commercialization-supported-by-favorable-government-policies-strong-pipeline-and-increased-licensing-activity.html) predicts that the stem cell therapy market will grow in value from $545m in 2012 to $972m in 2018, at a Compound Annual Growth Rate (CAGR) of 10%.

Buy your copy of this report @ http://www.reportsnreports.com/Purchase.aspx?name=210795. Alternatively, Request A Sample @ http://www.reportsnreports.com/contacts/RequestSample.aspx?name=210795 to help make your purchase decision.

Companies covered in this report include: Stempeutics Research, Reliance Life Sciences, International Stem Cell Services, Shenzhen Beike Biotechnology, JCR Pharmaceuticals, ES Cells International (Subsidiary of BioTime, Inc), Stem Cell Technologies I, Pharmicell and Medipost. Equipped with 70 Tables and 60+ Figures, the report Stem Cell Therapy Market in Asia-Pacific to 2018 - Commercialization Supported by Favorable Government Policies, Strong Pipeline and Increased Licensing Activity provides an in-depth analysis on stem cell research and development in India, China, Japan, South-Korea and Singapore. The research offers market analysis and forecasts for CABG, LSCT, Type 1 DM, Type 2 DM, Hearticellgram, Cerecellgram, Cartistem and Cupistem. The report also provides information on trends and pipelines. In addition to this, the report covers market drivers and challenges for stem cell research market.

Explore more reports on the Stem Cell Market @ http://www.reportsnreports.com/tags/stem-cell-market-research.html.

About Us:

ReportsnReports.com (http://www.reportsnreports.com/) is an online market research reports library of 200,000+ in-depth studies of over 5000 micro markets. Our database includes reports by leading publishers from across the globe. We provide 24/7 online and offline support service to our customers.

Visit link:
APAC Stem Cell Research & Therapy Market a “Growth Engine” for Region’s Scientific Ambitions Says A New Market ...

Recommendation and review posted by simmons

SAN DIEGO--(BUSINESS WIRE)--

ACADIA Pharmaceuticals Inc. (ACAD), a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders, today announced that it will receive funding from Fast Forward, LLC, a not-for-profit organization established by the National Multiple Sclerosis Society, and EMD Serono, a subsidiary of Merck KGaA, Darmstadt, Germany. This funding will support ACADIA research, to be conducted in collaboration with Dr. Rhonda Voskuhl of UCLA, directed at using AC-186, ACADIAs proprietary and selective estrogen receptor (ER)-beta agonist, as a new approach to the treatment of multiple sclerosis (MS).

We are grateful for the commitment by Fast Forward and EMD Serono, which will enable us to expand on promising research in our ER-beta program and broaden its application to MS, said Uli Hacksell, Ph.D., ACADIAs Chief Executive Officer. We also are excited to collaborate on this research with Dr. Voskuhl, Professor and Program Director at the UCLA Department of Neurology, who is a recognized expert in MS and neuroprotection.

Currently, there are multiple immunology-based, disease-modifying drugs approved for the treatment of relapsing forms of MS. In contrast, no drug is currently approved for the treatment of progressive forms of MS and no currently available drugs were developed to specifically target neurodegeneration in MS. A new MS drug with neuroprotective properties would fill this major unmet medical need. Studies in animal models of MS suggest that selective ER-beta receptor agonists provide neuroprotective effects while avoiding stimulation of ER-alpha receptors, which are believed to mediate toxicity. In this new program, AC-186, a selective ER-beta agonist discovered by ACADIA, will be evaluated to further test this hypothesis.

Fast Forward and EMD Serono will provide up to $545,000 to support preclinical studies with AC-186 designed to further evaluate pharmacokinetics and its therapeutic potential in preclinical models of MS. This funding will be provided by the parties Accelerating Commercial Development Fund, which is allocated to for-profit entities and is designed to accelerate the development of research discoveries into new or improved therapies for people with MS.

We are pleased to partner with ACADIA and UCLA on this innovative approach to targeting MS neurodegeneration, said Dr. Timothy Coetzee, Chief Research Officer at the National MS Society and Fast Forward. This is another example of our steadfast commitment to seek out and support promising new therapeutic approaches that address critical unmet needs and could improve the lives of patients with MS.

About Multiple Sclerosis

Multiple sclerosis (MS) is a chronic, inflammatory condition of the central nervous system and is the most common, non-traumatic, disabling neurological disease in young adults. It is estimated that approximately two million people have MS worldwide. While symptoms can vary, the most common symptoms of MS include blurred vision, numbness or tingling in the limbs and problems with strength and coordination. The relapsing forms of MS are the most common.

About Fast Forward, LLC

Fast Forward, LLC, established by the National Multiple Sclerosis Society as part of a comprehensive approach to MS research and treatment, focuses on speeding promising research discoveries towards commercial drug development. Fast Forward accelerates the development of treatments for MS by connecting university-based MS research with private-sector drug development and by funding small biotechnology/pharmaceutical companies to develop innovative new MS therapies and repurpose FDA-approved drugs as new treatments for MS. For more information, please visit http://www.fastforward.org.

View original post here:
ACADIA Pharmaceuticals to Receive Funding from Fast Forward and EMD Serono for Multiple Sclerosis Program

Recommendation and review posted by simmons

ROCKLAND, Mass. and NEW YORK, Dec. 20, 2012 /PRNewswire/ --EMD Serono, Inc., a subsidiary of Merck KGaA, Darmstadt, Germany, and Fast Forward LLC, a wholly-owned subsidiary of the National Multiple Sclerosis Society, today announced the third group of recipients to receive funding through their collaboration, which is designed to accelerate innovation and commercial development of multiple sclerosis (MS) therapies.

(Logo: http://photos.prnewswire.com/prnh/20121220/SF32295LOGO-a)

(Logo: http://photos.prnewswire.com/prnh/20121220/SF32295LOGO-b)

The awards total approximately $1.4 million and will be distributed from the Accelerating Commercial Development Fund created by EMD Serono and Fast Forward to encourage early-stage drug discovery for MS. The Accelerating Commercial Development Fund is open to early-stage for-profit commercial organizations that have achieved Series A or comparable investment funding. The other fund in the collaboration, the Accelerating Innovation Fund, is open to academic institutions, non-profit research organizations, and seed-stage for-profit commercial organizations.

EMD Serono and Fast Forward distributed a call for proposals to fund projects directed towards the development of therapies to prevent, treat or reverse nervous system damage in MS. These priority research areas were determined by a joint steering committee comprised of Fast Forward staff and representatives from EMD Serono and Merck KGaA.

The following organizations will receive funding:

Under the Accelerating Commercial Development Program:

"We are pleased to announce the 2012 funding recipients whose work has the potential to broaden our knowledge and understanding of MS, and hopefully, result in new treatment options for people living with this disease," said Bernhard Kirschbaum, PhD, Executive Vice President, Global Research and Development at Merck Serono, a division of Merck KGaA, Darmstadt, Germany. "Our ongoing collaboration with Fast Forward reflects our sustained commitment to leveraging internal as well as external expertise in furthering scientific excellence in MS."

EMD Serono and Fast Forward entered into an initial two-year, worldwide agreement in March 2009, and recently extended the collaboration. As part of the up to $19 million collaborative agreement with Fast Forward, EMD Serono provides the majority of funding for the research awards, with Fast Forward contributing 10 percent of the total financing of the awards disseminated from each of the two funds.

"Advancing new treatments for people with MS requires continuing research and discovery in order to find new and better treatments," said Dr. Timothy Coetzee, Chief Research Officer at the National MS Society and Fast Forward. "We are pleased to have the opportunity to advance research through the continued collaboration between Fast Forward and EMD Serono. We remain committed to being a driving force of research and treatment options to stop MS, restore function, and end MS forever, and we look forward to learning more from the results of these innovative projects."

Read the rest here:
EMD Serono, Inc. and Fast Forward, LLC Announce Recipients of Funding for Multiple Sclerosis Research

Recommendation and review posted by simmons

"Stem Cell Strategies for Spinal Cord Injury - Managing the Microenvironment" - Dr. Aileen Anderson
Dr. Anderson talks about how to bridge the junction between basic neuroscience and identifying translational strategies in SCI that will promote recovery of function.From:unite2fightparalysisViews:1 0ratingsTime:30:30More inNonprofits Activism

Read the original post:
"Stem Cell Strategies for Spinal Cord Injury - Managing the Microenvironment" - Dr. Aileen Anderson - Video

Recommendation and review posted by sam

"The Role of Peripheral Nerve Surgery in Restoring Motor Control" - Dr. Justin Brown
Dr. Brown gives an outstanding video presentation on his work and results with peripheral nerve based approaches to functional optimization in the chronic stage of spinal cord injury.From:unite2fightparalysisViews:0 0ratingsTime:26:32More inNonprofits Activism

See the rest here:
"The Role of Peripheral Nerve Surgery in Restoring Motor Control" - Dr. Justin Brown - Video

Recommendation and review posted by sam

"Neural Repair of Cauda Equina and Conus Medullaris Forms of Spinal Cord Injury" - Dr. Leif Havton
Dr. Havton discusses new strategies developed in his lab for treatment of these specific forms of spinal cord injury.From:unite2fightparalysisViews:0 0ratingsTime:34:33More inNonprofits Activism

Read the rest here:
"Neural Repair of Cauda Equina and Conus Medullaris Forms of Spinal Cord Injury" - Dr. Leif Havton - Video

Recommendation and review posted by sam

Dean Tozer of Shire Regenerative Medicine - at Stem Cells USA Regenerative Medicine Congress 2012
Dean Tozer, Senior Vice President of Corporate Development at Shire Regenerative Medicine, spoke at the Stem Cells USA Regenerative Medicine Congress 2012 on the topic, #39;Going all-in: Shire #39;s $750M bet on Shire Regenerative Medicine. #39; The Stem Cells Regenerative Medicine Congress is where pharma, biotech, academia, government and investors come to uncover the technologies, strategies and business models that will help get stem cell and regenerative medicine treatments to market faster and more cost effectively. For more information, go to http://www.terrapinn.com/stemcellsusa. Or, check out our blog at blogs.terrapinn.com/total-biopharma for up to date information on the stem cells, RM and cord blood banking and therapeutics sectors.From:biopharmachannelViews:0 0ratingsTime:18:23More inScience Technology

Continued here:
Dean Tozer of Shire Regenerative Medicine - at Stem Cells USA

Recommendation and review posted by sam

William Prather of Pluristem on treating Aplastic Anemia with stem cells - at Stem Cells USA 2012
William Prather, Sr. VP Corporate Development at Pluristem, spoke at the Stem Cells USA Regenerative Medicine Congress 2012 on the topic, #39;Treating Aplastic Anemia with PLX Stem Cells. #39; The Stem Cells Regenerative Medicine Congress is where pharma, biotech, academia, government and investors come to uncover the technologies, strategies and business models that will help get stem cell and regenerative medicine treatments to market faster and more cost effectively. For more information, go to http://www.terrapinn.com/stemcellsusa. Or, check out our blog at blogs.terrapinn.com/total-biopharma for up to date information on the stem cells, RM and cord blood banking and therapeutics sectors.From:biopharmachannelViews:0 0ratingsTime:21:02More inScience Technology

Original post:
William Prather of Pluristem on treating Aplastic Anemia with stem cells - at Stem Cells USA 2012 - Video

Recommendation and review posted by sam

Teresa Leezer of Rhinocyte on neurodegenerative conditions - at Stem Cells USA RM Congress 2012
Teresa Leezer, COO of Rhinocyte, spoke at the Stem Cells USA Regenerative Medicine Congress 2012 on the topic, #39;Using autologous olfactory epithelial cells to treat neurodegenerative conditions. #39; The Stem Cells Regenerative Medicine Congress is where pharma, biotech, academia, government and investors come to uncover the technologies, strategies and business models that will help get stem cell and regenerative medicine treatments to market faster and more cost effectively. For more information, go to http://www.terrapinn.com/stemcellsusa. Or, check out our blog at blogs.terrapinn.com/total-biopharma for up to date information on the stem cells, RM and cord blood banking and therapeutics sectors.From:biopharmachannelViews:0 0ratingsTime:14:58More inScience Technology

Read more:
Teresa Leezer of Rhinocyte on neurodegenerative conditions - at Stem Cells USA

Recommendation and review posted by sam

Michael West of BioTime on hES cell-based therapies - at Stem Cells USA RM Congress 2012
Michael West, CEO of BioTime, spoke at the Stem Cells USA Regenerative Medicine Congress 2012 on the topic, #39;Second generation hES cell-based therapies: achieving purity and scalability in the midst of diversity. #39; The Stem Cells Regenerative Medicine Congress is where pharma, biotech, academia, government and investors come to uncover the technologies, strategies and business models that will help get stem cell and regenerative medicine treatments to market faster and more cost effectively. For more information, go to http://www.terrapinn.com/stemcellsusa. Or, check out our blog at blogs.terrapinn.com/total-biopharma for up to date information on the stem cells, RM and cord blood banking and therapeutics sectors.From:biopharmachannelViews:0 0ratingsTime:23:31More inScience Technology

Read this article:
Michael West of BioTime on hES cell-based therapies - at Stem Cells USA

Recommendation and review posted by sam

Ed Field of Cytomedix on biotech collaboration in RM - at Stem Cells USA RM Congress 2012
Ed Field, Chief Operating Officer of Cytomedix, spoke at the Stem Cells USA Regenerative Medicine Congress 2012 on the topic, #39;Biotech collaboration in RM: Cytomedix #39;s acquisition of Aldagen. #39; The Stem Cells Regenerative Medicine Congress is where pharma, biotech, academia, government and investors come to uncover the technologies, strategies and business models that will help get stem cell and regenerative medicine treatments to market faster and more cost effectively. For more information, go to http://www.terrapinn.com/stemcellsusa. Or, check out our blog at blogs.terrapinn.com/total-biopharma for up to date information on the stem cells, RM and cord blood banking and therapeutics sectors.From:biopharmachannelViews:0 0ratingsTime:24:03More inScience Technology

The rest is here:
Ed Field of Cytomedix on biotech collaboration in RM - at Stem Cells USA

Recommendation and review posted by sam

Alternative funding sources for regenerative medicine - panel discussion at Stem Cells USA 2012
Stem Cells USA Regenerative Medicine Congress 2012 featured an exciting panel discussion on the topic, #39;Looking to alternative funding sources for the regenerative medicine field. #39; Panelists included: Ed Field, Chief Operating Officer, Cytomedix Dan Gincel, Director, Maryland Stem Cell Research Fund Elona Baum, General Counsel, California Institute for Regenerative Medicine (CIRM) Brock Reeve, Executive Director, Harvard Stem Cell Institute The Stem Cells Regenerative Medicine Congress is where pharma, biotech, academia, government and investors come to uncover the technologies, strategies and business models that will help get stem cell and regenerative medicine treatments to market faster and more cost effectively. For more information, go to http://www.terrapinn.com/stemcellsusa. Or, check out our blog at blogs.terrapinn.com/total-biopharma for up to date information on the stem cells, RM and cord blood banking and therapeutics sectors.From:biopharmachannelViews:0 0ratingsTime:50:04More inScience Technology

View post:
Alternative funding sources for regenerative medicine - panel discussion at Stem Cells USA 2012 - Video

Recommendation and review posted by sam

Mathew Vincent of ACT on hESC derived RPE cells - at Stem Cells USA RM Congress 2012
Mathew Vincent, Director of Business Development at Advanced Cell Technology, spoke at the Stem Cells USA Regenerative Medicine Congress 2012 on the topic, #39;Meaningful clinical results with hESC derived RPE cells in patients with SMD and Dry AMD. #39; The Stem Cells Regenerative Medicine Congress is where pharma, biotech, academia, government and investors come to uncover the technologies, strategies and business models that will help get stem cell and regenerative medicine treatments to market faster and more cost effectively. For more information, go to http://www.terrapinn.com/stemcellsusa. Or, check out our blog at blogs.terrapinn.com/total-biopharma for up to date information on the stem cells, RM and cord blood banking and therapeutics sectors.From:biopharmachannelViews:0 0ratingsTime:25:03More inScience Technology

Continued here:
Mathew Vincent of ACT on hESC derived RPE cells - at Stem Cells USA

Recommendation and review posted by sam

UMBILICAL CORD STEM CELL THERAPY
We are a Ministry of Health sanctioned group of three hospitals in South China providing adult stem cell and Cancer biotherapy treatments for patients locally and from around the world. http://www.hopestemcell.com It has been proven time and time again that adult stem cells not embryonic stem cells are safe and have remarkable results. We offer highly skilled, personalized and the most cost effective care in China which is 10 years ahead of other countries in stem cell treatment and it is delivered with the maximum regard for your safety.From:Randy RobinsonViews:0 0ratingsTime:01:54More inNews Politics

See the article here:
UMBILICAL CORD STEM CELL THERAPY - Video

Recommendation and review posted by Bethany Smith

Stem Cell Therapy at Integra Medical Center IMC
New Project 64From:OmarGonzalezMDViews:0 0ratingsTime:06:12More inScience Technology

View post:
Stem Cell Therapy at Integra Medical Center IMC - Video

Recommendation and review posted by Bethany Smith

Marie Csete of AABB on AABB accreditation - at World Cord Blood Congress 2012
Marie Csete, Director of Cell Therapy at AABB, spoke at the World Cord Blood Congress 2012 on the topic, #39;AABB accreditation: a global approach to collaboration, innovation and quality. #39; World Cord Blood Congress is where private and public cord blood banks, pharma and biotechs, academia and government come to debate advances in cord blood banking and therapeutics. For more information, go to http://www.terrapinn.com/cordblood. Or, check out our blog at blogs.terrapinn.com/total-biopharma for up to date information on the stem cells, RM and cord blood banking and therapeutics sectors.From:biopharmachannelViews:0 0ratingsTime:21:41More inScience Technology

Go here to read the rest:
Marie Csete of AABB on AABB accreditation - at World Cord Blood Congress 2012 - Video

Recommendation and review posted by Bethany Smith